Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027923 · ClinicalTrials.gov registry record · Phase 1
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01027923 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants.
The verdict
NCT01027923, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
In this phase I extension study, the investigators seek to test the safety of both higher doses of plerixafor as well as intravenous dosing to maximize inhibition of the target, CXCR4.
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Plerixafor
- DRUG Mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01027923
The ClinicalTrials.gov registry entry for NCT01027923 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Etoposide is the first listed.
NCT01027923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01027923 about?
NCT01027923 is a clinical study titled "IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)". In this phase I extension study, the investigators seek to test the safety of both higher doses of plerixafor as well as intravenous dosing to maximize inhibition of the target, CXCR4.
What is the current status of trial NCT01027923?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-05. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01027923?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Plerixafor (DRUG), Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT01027923?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.